(1) World Health Organization annual report, Leishmaniasis fact sheet 2020. Published by WHO, 20 My 2020.
(2) Husein-ElAhmed H, Gieler U and Steinhoff M. Evidence supporting the enhanced efficacy of pentavalent antimonials with adjuvant therapy for cutaneous leishmaniasis: a systematic review and meta-analysis. J. Eur. Acad. Dermatol. Venereol. (2020) 34: 2216-28.
(3) MWare JA, O'Connel EM, Brown T and Wetzler L. Efficacy and Tolerability of Miltefosine in the Treatment of Cutaneous Leishmaniasis. Clin. Infect. Dis. (2020) 73: 7.
(4) Li Y, Chen F, Li Z, Li C and Zhang Y. Identification and Functional Characterization of Sesquiterpene Synthases from Xanthium strumarium. Plant and Cell Physiol. (2016) 57: 630-41.
(5) Fan L, Zhang C, Ai L, Wang L, Li L, Fan W, Li R, He L, Wu C and Huang Y.Traditional uses, botany, phytochemistry, pharmacology, separation and analysis technologies of Euonymus alatus (Thunb.) Siebold: A comprehensive review. J. Ethnopharmacol. (2020) 259: 112942.
(6) Fan W, Fan L, Peng C, Zhang Q, Wang L, Li L, Wang J, Zhang D, Peng W and Wu C. Traditional Uses, Botany, Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Xanthium strumarium L.: A Review. Molecules (2019) 24: 359.
(7) Tao L, Fan F, Liu Y, Li W, Zhang L, Ruan J, Shen C, Sheng X, Zhu Z, Wang A, Chen W, Huang S and Lu Y. Concerted suppression of STAT3 and GSK3beta is involved in growth inhibition of non-small cell lung cancer by Xanthatin. PLoS One (2013) 8: 81945.
(8) Tao L, Cao Y, Wei Z, Jia Q, Yu S, Zhang J, Wang A, Woodgett JR and Lu Y. Xanthatin triggers Chk1-mediated DNA damage response and destabilizes Cdc25C via lysosomal degradation in lung cancer cells. Toxicol. Appl. Pharmacol (2017) 337: 85-94.
(9) Liu M, Xiao CG, Sun MW, Tan MJ, Hu LH and Yu Q. Xanthatin inhibits STAT3 and NF-kappaB signalling by covalently binding to JAK and IKK kinases. J. Cell. Mol. Med (2019) 23: 4301-12.
(10) Nibret E, Youns M, Krauth-Siegel RL and Wink L. Biological activities of xanthatin from Xanthium strumarium leaves. Phytother. Res (2011) 25: 1883-90.
(11) Han T, Zhang H, Li HL and Zhang QY. Composition of supercritical fluid extracts of some Xanthium species from China. Chem. Nat. Compd. (2008) 44: 814-6.
(12) Lavault M, Landreau A, Larcher G, Bouchara JP, Pagniez F, Pape P and Richomme D. Antileishmanial and antifungal activities of xanthanolides isolated from Xanthium macrocarpum. Fitoterapia (2005) 76: 363-6.
(13) Diskin C and Pålsson-McDermott EM. Metabolic Modulation in Macrophage Effector Function. Front. immunol. (2018) 9: 270.
(14) Mills C. M1 and M2 Macrophages: Oracles of Health and Disease. Crit. Rev. Immunol. (2012) 32: 463-88.
(15) Thapa B and K Lee. Metabolic influence on macrophage polarization and pathogenesis. BMB Rep. (2019) 52: 360-72.
(16) Viola A, Munari F, Sanchez-Rodriguez R and Scolaro T. The metabolic signature of macrophage responses. Front. immunol. (2019) 10: 1462.
(17) Rattigan, K.M., et al., Metabolomic profiling of macrophages determines the discrete metabolomic signature and metabolomic interactome triggered by polarising immune stimuli. PLoS ONE (2018) 13: 194126.
(18) Jiang Z, Kempinski C and Chappell J. Extraction and Analysis of Terpenes/Terpenoids. Curr. Protoc. Plant. Biol. (2016) 1: 345-58.
(19) Kurrey A, Sharma L, and Tiwari S. Evaluation of the Phytochemical and Antibacterial characteristics of leaf extracts of Xanthium strumarium L. against Bacteria. Int. J. Pharm. Sci. Res. (2020) 11: 725-29.
(20) Li, W, Wu Y, Zhang L, Yan LG, Yin FZ, Ruan JS, Chen ZP, Yang GM, Yan CP, Zhao D,Lu Y and Cai BC. Characterization of xanthatin: anticancer properties and mechanisms of inhibited murine melanoma in vitro and in vivo. Phytomedicine (2013) 20: 865-73.
(21) Shahbazi M, Zahedifard F, Taheri T, Taslimi Y, Jamshidi S, Shirian S, Mahdavi N, Hassankhani M, Daneshbod Y, Zarkesh-Esfahani SH, Papadopoulou B and Rafati S. Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis. PLoS ONE (2015) 10: 94-7.
(22) Ngure P, Tonui WK, Ingonga J and Mutai C. In vitro antileishmanial activity of extracts of Warburgia ugandensis (Canellaceae), a Kenyan medicinal plant. J. Med. Plant Res. (2009) 3: 61-6.
(23) Berman JD and Lee LS. Activity of antileishmanial agents against amastigotes in human monocyte-derived macrophages and in mouse peritoneal macrophages. J. Parasitol. (1984) 7: 220-5.
(24) Lauri I, Savorani F, Laccarino N, Zizza P, Pavone LM, Navooellino E, Engelsen SB and Randazzo A. Development of an optimized protocol for NMR metabolomics studies of human Colon Cancer Cell lines and first insight from testing of the protocol using DNA G-Quadruplex ligands as novel anti-cancer drugs. Metabolites (2016) 6: 4.
(25) Gupta N, Goyal N, Singha V, Bhakuni V, Roy R and Rastogi A. Characterization of intracellular metabolites of axenic amastigotes of Leishmania donovani by 1H NMR spectroscopy. Acta trop. (1999) 73: 121-33.
(26) Ahmadi M, Akbari Z, Alikhani M, Hajhosseini R, Zamani Z and Arjmand M. Metabolomics Based Study of the Antileishmanial Activity of Xanthium strumarium Leaf Extract on Promastigotes Phases of Leishmania major by Proton NMR Spectroscopy. Iran. J. Parasitol. (2019) 14: 258-68.
(27) Marco JA, Sanz-Cervera JF, Corral J, Carda M and Jekupovic J. Xanthanolides from Xanthium: Absolute configuration of xanthanol, isoxanthanol and their C-4 epimers. Phytochemistry (1993) 34: 1569-76.